Best Insurance-Friendly GLP-1 Telehealth Platforms in 2026
Getting your commercial insurance to cover Wegovy or Zepbound is possible — but it requires someone to do the prior-authorisation work, the documentation, and the appeals if the first submission is denied. Most people who give up assume the drug isn't covered; often the real issue is the PA submission wasn't complete.
The platforms here are built around getting that approval. They differ in clinical model, cost during the wait, and what happens if PA fails.
Quick reference: insurance-friendly platforms at a glance (May 2026)
| Platform | Membership fee (insured path) | PA support | What if PA fails? | Clinical model |
|---|---|---|---|---|
| Form Health | $99/mo | Active — ABOM MD + team | No compounded fallback; appeal focus | ABOM physician + RDN |
| Calibrate | $199/mo | Active — 90-day guarantee | Refund (minus $250) if no approval in 90 days | Biweekly coaching, no specialist |
| Mochi Health | $79/mo | Active | Compounded fallback at $99–199/mo | Async prescriber, PA support team |
| Ro Body | $149/mo | Insurance concierge | Branded direct via NovoCare — no compounded | Async prescriber, coaching |
Medication cost on top of these fees depends on your plan — typically $0–$50/month copay after approval with manufacturer savings cards, or NovoCare/LillyDirect pricing if you go cash-pay.
What you are actually paying for
The platform fee (Calibrate's $199/month, Form's $99/month, etc.) does not cover your medication. Medication fills separately through your pharmacy after approval. What the fee covers:
- The prescriber relationship — a licensed provider to write and manage your prescription
- PA submission and management — the clinical documentation, coding, and appeals work
- Ongoing monitoring — check-ins, dose adjustments, labs
- Coaching/curriculum — varies by platform
After PA approval, most insured patients pay $0–$50/month for Wegovy or Zepbound with the manufacturer savings card (commercial insurance only, excluding Medicare/Medicaid). Your total ongoing cost is the platform fee plus that copay.
During the PA wait period — which can run 2–12 weeks — you are paying the platform fee while the drug hasn't been approved yet. This is the main cost friction to understand upfront.
Platform breakdown
Form Health — best clinical quality + Medicare
Form Health sits at the most clinically rigorous end of the GLP-1 telehealth spectrum. Every patient gets an ABOM-certified obesity medicine physician — not a general practitioner or NP — paired with a Registered Dietitian. ABOM certification requires specialty-level training and an examination specifically on obesity medicine, beyond primary board requirements.
For insured patients, the membership is $99/month. It covers physician visits, RDN appointments, unlimited messaging, insurance navigation, and active PA management. Labs and medication bill separately through insurance.
Form Health accepts Medicare, which makes it a rare option for the 65+ demographic. As of July 2026, Medicare covers Zepbound KwikPen at a $50/month copay under the Medicare GLP-1 Bridge — a Form Health physician can prescribe into that benefit.
What happens if PA fails: Form Health handles the appeals process, but it does not offer a compounded fallback. If insurance doesn't cover the drug, the path forward is branded direct (NovoCare or LillyDirect) at cash-pay rates.
Cash-pay path: $299/month membership + medication costs. Realistic minimum: ~$600/month at the lowest dose tier.
Full review: Form Health review.
Calibrate — best for structured programme + PA-or-refund guarantee
Calibrate is a 12-month structured programme: a four-phase metabolic reset curriculum with biweekly video coaching, an initial lab draw, and a PA-first approach to medication access. The membership is $199/month with a 3-month minimum ($597 upfront).
The distinctive feature is the guarantee: Calibrate commits to a 90-day window to secure insurance approval. If they cannot get PA approved within 90 days, you are eligible for a refund minus a $250 processing fee.
Limitations: Calibrate is insurance-only. There is no compounded fallback if PA fails, and no Medicare or Medicaid coverage. No patients over 64. No cash-pay medication path. For patients who need a decision in weeks rather than months, or who don't have commercial insurance, Calibrate is a non-starter.
The 90-day wait while paying $597+ is the most common patient frustration — and PA times have stretched longer than 90 days for some members based on BBB complaint records.
Full review: Calibrate review.
Mochi Health — best for insurance + compounded fallback
Mochi is the only platform on this list that offers both active prior-authorisation support and a compounded GLP-1 fallback if PA fails. While your PA is pending, Mochi can put you on compounded semaglutide ($99/month) or compounded tirzepatide ($199/month) plus the $79/month membership, giving you access to the drug while waiting for branded coverage.
The PA support model: Mochi's clinical team manages the submission and appeals. If PA is approved, you transition to the branded drug at your insurance copay (typically $0–$50/month with the savings card) while keeping the $79/month membership.
The fallback path is meaningful — Hims patients who lost compounded access and Calibrate patients who didn't get PA in time have used Mochi as a transition provider. Having a compounded fallback removes the "all or nothing" dynamic that makes Calibrate's 90-day wait high-stakes.
Material risk: Eli Lilly's patent lawsuit against Mochi is proceeding (survived motion to dismiss, April 2026). The compounded fallback carries the same legal-continuity risk as any remaining 503A operator.
Full review: Mochi Health review.
Ro Body — best for Novo-partnered branded access + insurance concierge
Ro is a Novo Nordisk NovoCare official telehealth partner, prescribing only branded medications — Wegovy, Ozempic, Zepbound, Mounjaro. No compounded drugs. The membership is $149/month (or $74/month on an annual plan) on top of NovoCare drug pricing.
Ro's PA timeline is 2–4 weeks, which is faster than Calibrate's 90-day outer bound. The insurance concierge manages the prior-auth process and follows up with your insurer.
What you are paying for beyond the PA: a branded-only platform means your medications are FDA-approved products, there is no compounding legal-continuity risk, and the drug cost is predictable via NovoCare pricing. If PA fails, Ro patients access Wegovy at NovoCare's $349/month flat rate — no further membership overhead required (though you would lose the prescriber/check-in layer without the membership).
Full review: Ro Body review.
How to choose
If clinical quality is the priority and you have commercial insurance or Medicare: Form Health. The ABOM physician + RDN model is the highest clinical standard available in GLP-1 telehealth; the $99/month insured path is reasonable for that level.
If you want a structured programme with a PA guarantee: Calibrate — but read the cancellation terms carefully and understand the 90-day wait with $597 at risk.
If you want a fallback plan if PA fails: Mochi. The ability to start on compounded semaglutide the week you enrol, while the PA process runs, makes the wait less costly and less uncertain.
If you want a fast PA process and branded-only drugs: Ro Body. Fewer hoops, NovoCare partnership, and a 2–4 week PA estimate.
For patients without insurance or with plans that don't cover GLP-1s for obesity, see the cash-pay GLP-1 comparison. For a full cross-provider comparison including all active platforms, see the provider comparison.
Frequently asked questions
Does insurance cover GLP-1 drugs for weight loss?
Some commercial plans cover Wegovy (semaglutide) and Zepbound (tirzepatide) for obesity, but coverage is uneven. As of 2025, approximately 49% of employers with 500+ employees offered GLP-1 coverage for obesity. Medicare does not cover GLP-1s for obesity; it covers them for type 2 diabetes. Coverage typically requires prior authorisation, step therapy, and documented BMI and comorbidities. The platforms on this page specialise in navigating that process.
What is prior authorisation for GLP-1 drugs?
Prior authorisation (PA) is your insurance plan's requirement that your prescriber document medical necessity before they will cover the medication. For Wegovy and Zepbound, most plans require: BMI ≥30 (or ≥27 with a comorbidity like hypertension or T2D), documentation that other weight-loss attempts have failed, and sometimes step therapy (trying cheaper drugs first). A PA-savvy telehealth platform submits this documentation on your behalf and handles appeals if the initial request is denied.
How long does prior authorisation take for GLP-1 drugs?
Typically 2–12 weeks, depending on your insurance plan and how complete the initial submission is. Some plans respond in days; others take months. Calibrate guarantees a 90-day window and offers a refund (minus $250) if PA isn't secured in that time. Form Health and Mochi also handle PA actively. During the waiting period, most platforms charge their membership fee even while the drug isn't yet approved.
What happens if my insurance denies prior authorisation for Wegovy?
You have three paths: (1) appeal the denial — Form Health, Calibrate, and Mochi all handle appeals for their patients; (2) switch to a cash-pay compounded option while the appeal is in progress (Mochi offers this); or (3) apply for NovoCare ($349/month) or LillyDirect ($299–449/month). The platforms on this page differ in what happens on denial — some have a clear compounded fallback; others are insurance-only.
Does Form Health accept Medicare?
Yes — Form Health is one of very few GLP-1 telehealth platforms that accepts Medicare. Note that as of July 1, 2026, Medicare covers Zepbound (tirzepatide KwikPen) for obesity at a $50/month copay through the Medicare GLP-1 Bridge. A Form Health physician can prescribe to that benefit. Other platforms like Calibrate do not accept Medicare or patients over 64.